CUTTS HepC: Catalysing uptake of under-utilised tools & treatment simplification for HepC

Objective

Led by the Médecins du Monde Consortium, the project will be implemented in Georgia, Armenia, and Tanzania. Its core goal is to embed hepatitis C testing and treatment within harm reduction programs while piloting two innovative tools to reduce injecting-related risks.

Project components

Hepatitis C model of care

This study will trial a simplified, same-day testing and treatment model using a shortened rapid test read-time and pooled RNA testing to monitor cure and reinfection. The goal: streamline care and reduce diagnostic and treatment delays.

Low dead space syringes (LDSS) study

Led in partnership with INPUD, this study will assess community preferences, uptake, and the impact of low dead space syringes distribution on reducing HIV and hepatitis C transmission.

Long-acting Buprenorphine trial

In Tanzania, the study will evaluate feasibility, acceptability, effectiveness, and cost-effectiveness of long-acting buprenorphine to support future scale-up and pricing strategies.

Approach

Each component emphasizes real-world, community-led research. Findings will feed into national and global policies and guidelines, while supporting broader harm reduction strategies and market access through demand generation and price negotiation.

Community impact

The CUTTS HepC Project will directly benefit participants—many of whom lack access to these interventions—and create a path for broader availability and impact beyond the study.

Timeline

2023–2027.